August 9th, 2025: Novo Nordisk Increases Trademark Lawsuits Over Compounded Ozempic Products Novo Nordisk has intensified its legal campaign to protect the Ozempic trademark, filing 14 additional federal lawsuits against pharmacies, telehealth providers, and other sellers marketing compounded semaglutide products
What is BioBoost/LipoB
These include, extreme tiredness, a lack of energy, pins and needles, muscle weakness, disturbed vision, mouth ulcers, a sore and red tongue, and cognitive or psychological concerns such as depression, confusion, and difficulty with memory, understanding or judgement
In addition, injecting glucose into the intestine was able to stimulate the production of more insulin than injecting it into the vein